A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
DUBLIN, Dec. 15, 2021 -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the entry...
DUBLIN, Ireland, Sept. 09, 2021 -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021. Quarter 2...
Conference Call Scheduled for September 9, 2021 at 11:00 am EASTERNDUBLIN, Ireland, Aug. 31, 2021 -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report...
DUBLIN, Ireland, July 16, 2021 -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021. HIV Testing (TrinScreen™ HIV) Trinity Biotech has been the main confirmatory test provider for the detection of the HIV virus on the African...
DUBLIN, Ireland, May 25, 2021 -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021. Quarter 1 Results...
Conference Call Scheduled for May 25, 2021 at 11:00 am EASTERNDUBLIN, Ireland, May 19, 2021 -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial...
DUBLIN, Ireland, March 30, 2021 -- Trinity Biotech plc (Nasdaq: TRIB) has submitted its new HIV screening product, TrinScreen™ HIV, to the World Health Organisation (WHO) for approval. This product, once approved, will allow the Company to build on its strong...
DUBLIN, Ireland, March 25, 2021 -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2020 and fiscal year...
Conference Call Scheduled for March 25, 2021 at 11:00 am EASTERNDUBLIN, Ireland, March 23, 2021 -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report...
DUBLIN, Ireland, Jan. 05, 2021 -- Trinity Biotech plc (Nasdaq: TRIB) has achieved CE Mark approval and registration for its Covid-19 IgG ELISA antibody test, the Captia™ SARS-CoV-2 IgG ELISA. Trinity Biotech has launched the test in countries throughout the...